Background
Phase 3, multicenter, randomized controlled trial (UKALL 2003, ISRCTN07355119). N=3,093 children and young adults aged 1–24 years with newly diagnosed ALL treated across UK centers 2003–2011. All received the standard UKALL backbone. Patients with clinical standard-risk and intermediate-risk ALL were MRD-screened at end of induction. The randomized question: among patients with high-risk MRD (≥10⁻⁴ / ≥0.01% at end of induction), did augmented post-remission therapy improve outcome vs standard treatment? First randomized trial validating MRD-guided treatment intensification in pediatric ALL. Published Lancet Oncology 2014.
Interventions and follow up
Arm A (standard): Standard MRC pediatric ALL regimen with risk-stratified post-induction therapy by MRD
Arm B (augmented): Augmented BFM consolidation ± escalated Capizzi-style methotrexate for high-risk MRD patients
Primary endpoint: 5-year EFS and OS in children/young adults (1–24 yr)
mFollow up: ~5 years
Arm B (augmented): Augmented BFM consolidation ± escalated Capizzi-style methotrexate for high-risk MRD patients
Primary endpoint: 5-year EFS and OS in children/young adults (1–24 yr)
mFollow up: ~5 years
Results
5-year EFS (augmented vs standard, MRD high-risk): 81% vs 73%, OR 0.61 (95% CI 0.39–0.98), P=.04
5-year OS (augmented vs standard): 91% vs 88%, OR 0.67 (0.38–1.17), P=.16 — NS
MRD low-risk (<0.01%) 5-year EFS: 90% on standard therapy
MRD assessment feasibility: data available for ~75% of eligible patients
5-year OS (augmented vs standard): 91% vs 88%, OR 0.67 (0.38–1.17), P=.16 — NS
MRD low-risk (<0.01%) 5-year EFS: 90% on standard therapy
MRD assessment feasibility: data available for ~75% of eligible patients
Adverse events
Overall toxicity: Augmented arm had higher grade ≥3 toxicity, 45% vs 34% (P=.02)
Most common excess toxicities: asparaginase hypersensitivity, pancreatitis, mucositis, gastrointestinal toxicity
Tolerability: Augmentation tolerable but with clinically meaningful incremental toxicity
Most common excess toxicities: asparaginase hypersensitivity, pancreatitis, mucositis, gastrointestinal toxicity
Tolerability: Augmentation tolerable but with clinically meaningful incremental toxicity
Conclusions
MRD-guided treatment intensification — augmenting therapy in children/young adults with ≥0.01% MRD at end of induction — significantly improved 5-year EFS (81% vs 73%) in the clinical standard-risk and intermediate-risk population. This was the first randomized proof that MRD-stratified treatment could improve outcomes in pediatric ALL.
Key Limitations
OS difference did not reach significance (P=.16), so the benefit is on EFS rather than survival. MRD data were missing for ~25% of eligible patients, introducing potential ascertainment bias. The augmented regimen carries meaningful added toxicity (45% vs 34% grade ≥3). Conducted 2003–2011; predates modern immunotherapy (blinatumomab, CAR-T) and contemporary MRD methods (NGS), which have refined risk stratification.
Clinical Context
UKALL 2003 established end-of-induction MRD as the dominant risk-stratification tool in pediatric ALL and provided the first randomized validation of MRD-directed treatment intensification. ESMO and pediatric cooperative-group (UKALL, COG, BFM) protocols now universally incorporate MRD-guided risk stratification, sparing MRD-low-risk patients excess therapy while intensifying treatment for MRD-high-risk disease.